Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NASDAQ:LMAT NASDAQ:LQDA NASDAQ:PRCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.40+2.1%$6.89$5.81▼$14.38$611.83M0.83404,416 shs295,487 shsLMATLeMaitre Vascular$95.36+0.1%$87.40$71.42▼$109.58$2.16B0.79223,607 shs93,841 shsLQDALiquidia Technologies$27.68+0.8%$18.89$8.75▼$28.82$2.38B0.143.12 million shs2.17 million shsPRCTPROCEPT BioRobotics$40.17-0.4%$50.64$37.12▼$103.81$2.23B1.051.31 million shs769,202 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%-3.14%+13.50%+13.15%-23.63%LMATLeMaitre Vascular0.00%-4.95%+17.38%+16.05%+7.10%LQDALiquidia Technologies0.00%+3.13%+48.10%+84.17%+190.15%PRCTPROCEPT BioRobotics0.00%-2.57%-17.19%-31.45%-49.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.2159 of 5 stars3.40.00.00.02.93.31.3LMATLeMaitre Vascular2.6283 of 5 stars1.22.03.30.02.32.52.5LQDALiquidia Technologies3.5732 of 5 stars3.53.00.00.03.54.20.6PRCTPROCEPT BioRobotics3.4837 of 5 stars4.41.00.00.04.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.7585.81% UpsideLMATLeMaitre Vascular 2.40Hold$97.602.35% UpsideLQDALiquidia Technologies 3.00Buy$32.1116.01% UpsidePRCTPROCEPT BioRobotics 2.78Moderate Buy$74.8886.40% UpsideCurrent Analyst Ratings BreakdownLatest BVS, LQDA, PRCT, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$43.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $31.008/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.008/7/2025PRCTPROCEPT BioRoboticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $58.008/7/2025PRCTPROCEPT BioRoboticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$80.00 ➝ $55.008/6/2025LMATLeMaitre VascularCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$92.00 ➝ $95.008/6/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$95.007/22/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform7/15/2025PRCTPROCEPT BioRoboticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $68.007/9/2025PRCTPROCEPT BioRoboticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$564.14M1.08$0.59 per share12.58$2.80 per share2.64LMATLeMaitre Vascular$219.86M9.82$2.39 per share39.92$16.02 per share5.95LQDALiquidia Technologies$14M170.21N/AN/A$0.18 per share153.78PRCTPROCEPT BioRobotics$224.50M9.96N/AN/A$6.93 per share5.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23MN/AN/A16.09N/A-7.11%15.61%4.01%N/ALMATLeMaitre Vascular$44.04M$2.0646.2943.942.4520.08%13.67%9.14%10/30/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.55N/AN/AN/A-30.60%-23.73%-17.34%10/27/2025 (Estimated)Latest BVS, LQDA, PRCT, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/6/2025Q2 2025PRCTPROCEPT BioRobotics-$0.41-$0.35+$0.06-$0.35$75.67 million$79.18 million8/5/2025Q2 2025LMATLeMaitre Vascular$0.57$0.60+$0.03$0.60$62.48 million$63.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.84%N/A38.83%14 YearsLQDALiquidia TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ALatest BVS, LQDA, PRCT, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/30/2025LMATLeMaitre Vascularquarterly$0.200.9%8/21/20258/21/20259/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99LMATLeMaitre Vascular0.4613.9611.74LQDALiquidia Technologies9.842.492.41PRCTPROCEPT BioRobotics0.139.217.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%LMATLeMaitre Vascular84.64%LQDALiquidia Technologies64.54%PRCTPROCEPT BioRobotics89.46%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%LMATLeMaitre Vascular9.50%LQDALiquidia Technologies26.50%PRCTPROCEPT BioRobotics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableLMATLeMaitre Vascular49022.64 million20.49 millionOptionableLQDALiquidia Technologies5086.09 million63.28 millionOptionablePRCTPROCEPT BioRobotics43055.64 million51.96 millionOptionableBVS, LQDA, PRCT, and LMAT HeadlinesRecent News About These CompaniesNext Century Growth Investors LLC Has $7.40 Million Stock Holdings in PROCEPT BioRobotics Corporation $PRCTAugust 30 at 7:03 AM | marketbeat.comChamplain Investment Partners LLC Increases Stock Position in PROCEPT BioRobotics Corporation $PRCTAugust 30 at 6:38 AM | marketbeat.comWells Fargo Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)August 29 at 5:42 PM | theglobeandmail.comPrice T Rowe Associates Inc. MD Raises Position in PROCEPT BioRobotics Corporation $PRCTAugust 29 at 4:05 AM | marketbeat.comPROCEPT BioRobotics Corporation $PRCT Stake Boosted by Comerica BankAugust 28 at 6:56 AM | marketbeat.comPROCEPT BioRobotics Corporation $PRCT Stake Boosted by Capital Fund Management S.A.August 28 at 4:51 AM | marketbeat.comJump Financial LLC Raises Holdings in PROCEPT BioRobotics Corporation $PRCTAugust 27, 2025 | marketbeat.comHsbc Holdings PLC Buys 20,234 Shares of PROCEPT BioRobotics Corporation $PRCTAugust 27, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases 44,912 Shares of PROCEPT BioRobotics Corporation $PRCTAugust 27, 2025 | marketbeat.comThematics Asset Management Purchases 225,680 Shares of PROCEPT BioRobotics Corporation $PRCTAugust 26, 2025 | marketbeat.comCandriam S.C.A. Acquires New Position in PROCEPT BioRobotics Corporation $PRCTAugust 26, 2025 | marketbeat.comQuantbot Technologies LP Trims Position in PROCEPT BioRobotics Corporation $PRCTAugust 26, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Raises Position in PROCEPT BioRobotics Corporation $PRCTAugust 25, 2025 | marketbeat.comPROCEPT BioRobotics Corporation $PRCT Stock Holdings Lessened by Wellington Management Group LLPAugust 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in PROCEPT BioRobotics Corporation $PRCTAugust 25, 2025 | marketbeat.comAberdeen Group plc Sells 26,279 Shares of PROCEPT BioRobotics Corporation $PRCTAugust 24, 2025 | marketbeat.comAlgert Global LLC Raises Stock Holdings in PROCEPT BioRobotics Corporation $PRCTAugust 23, 2025 | marketbeat.comInvesco Ltd. Reduces Position in PROCEPT BioRobotics Corporation $PRCTAugust 23, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 9,391 Shares of PROCEPT BioRobotics Corporation $PRCTAugust 23, 2025 | marketbeat.comOsterweis Capital Management Inc. Has $10.12 Million Stake in PROCEPT BioRobotics Corporation $PRCTAugust 22, 2025 | marketbeat.comPROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts ShiftAugust 22, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVS, LQDA, PRCT, and LMAT Company DescriptionsBioventus NYSE:BVS$7.40 +0.15 (+2.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.28 -0.12 (-1.55%) As of 08/29/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.LeMaitre Vascular NASDAQ:LMAT$95.36 +0.09 (+0.09%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$95.28 -0.08 (-0.08%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Liquidia Technologies NASDAQ:LQDA$27.68 +0.22 (+0.80%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$27.60 -0.07 (-0.27%) As of 08/29/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.PROCEPT BioRobotics NASDAQ:PRCT$40.17 -0.17 (-0.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$40.73 +0.56 (+1.39%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
